NCT04488354View on ClinicalTrials.gov

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

August 31, 2036

Study Completion Date

August 31, 2036

Conditions
Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Chronic Lymphocytic Leukemia (CLL)Marginal Zone Lymphoma (MZL)Mantle Cell Lymphoma (MCL)Small Lymphocytic Lymphoma (SLL)Primary Mediastinal Large B Cell LymphomaTransformed Follicular LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaBurkitt Lymphoma
Interventions
COMBINATION_PRODUCT

CLBR001 and SWI019

No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy

Trial Locations (8)

10065

Weill Cornell Medical College - New York Presbyterian Hospital, New York

27157

Wake Forest Baptist Health, Winston-Salem

37203

Sarah Cannon Research Institute - Tennessee Oncology, Nashville

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

78229

Sarah Cannon Research Institute - Texas Transplant Institute, San Antonio

91010

City of Hope National Medical Center, Duarte

92093

University of California at San Diego, San Diego

All Listed Sponsors
lead

Calibr, a division of Scripps Research

OTHER